These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34591356)

  • 21. Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rational and design of the AWAKE-HF study.
    Khandwalla RM; Birkeland K; Heywood JT; Steinhubl S; McCague K; Fombu E; Grant D; Riebman JB; Owens RL
    ESC Heart Fail; 2019 Dec; 6(6):1313-1321. PubMed ID: 31638338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
    Morrow DA; Velazquez EJ; DeVore AD; Prescott MF; Duffy CI; Gurmu Y; McCague K; Rocha R; Braunwald E
    Eur Heart J; 2019 Oct; 40(40):3345-3352. PubMed ID: 31093657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
    Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM).
    Velicki L; Popovic D; Okwose NC; Preveden A; Tesic M; Tafelmeier M; Charman SJ; Barlocco F; MacGowan GA; Seferovic PM; Filipovic N; Ristic A; Olivotto I; Maier LS; Jakovljevic DG;
    Eur J Heart Fail; 2024 Jun; 26(6):1361-1368. PubMed ID: 38800948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: A randomized controlled study.
    Nesterov SV; Räty J; Nammas W; Maaniitty T; Galloo X; Stassen J; Laurila S; Vasankari T; Huusko J; Bax JJ; Saraste A; Knuuti J
    Eur J Heart Fail; 2024 Jan; 26(1):117-126. PubMed ID: 37905338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
    Seferovic JP; Claggett B; Seidelmann SB; Seely EW; Packer M; Zile MR; Rouleau JL; Swedberg K; Lefkowitz M; Shi VC; Desai AS; McMurray JJV; Solomon SD
    Lancet Diabetes Endocrinol; 2017 May; 5(5):333-340. PubMed ID: 28330649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
    Curtain JP; Adamson C; Docherty KF; Jhund PS; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJV
    JACC Heart Fail; 2023 Jul; 11(7):749-759. PubMed ID: 37407154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
    Vaduganathan M; Mentz RJ; Claggett BL; Miao ZM; Kulac IJ; Ward JH; Hernandez AF; Morrow DA; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Lefkowitz M; McMurray JJV; Braunwald E; Solomon SD
    Eur Heart J; 2023 Aug; 44(31):2982-2993. PubMed ID: 37210743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
    Zile MR; O'Meara E; Claggett B; Prescott MF; Solomon SD; Swedberg K; Packer M; McMurray JJV; Shi V; Lefkowitz M; Rouleau J
    J Am Coll Cardiol; 2019 Feb; 73(7):795-806. PubMed ID: 30784673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
    Chatur S; Neuen BL; Claggett BL; Beldhuis IE; Mc Causland FR; Desai AS; Rouleau JL; Zile MR; Lefkowitz MP; Packer M; McMurray JJV; Solomon SD; Vaduganathan M
    J Am Coll Cardiol; 2024 Jun; 83(22):2148-2159. PubMed ID: 38588927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
    Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
    Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.
    Mapelli M; Mattavelli I; Paolillo S; Salvioni E; Magrì D; Galotta A; De Martino F; Mantegazza V; Vignati C; Esposito I; Dell'Aversana S; Paolillo R; Capovilla T; Tamborini G; Nepitella AA; Filardi PP; Agostoni P
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1173-1184. PubMed ID: 37368004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
    Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Mann DL; Givertz MM; Vader JM; Starling RC; Shah P; McNulty SE; Anstrom KJ; Margulies KB; Kiernan MS; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; DeVore AD; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JAMA Cardiol; 2022 Jan; 7(1):17-25. PubMed ID: 34730769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
    Berg DD; Braunwald E; DeVore AD; Lala A; Pinney SP; Duffy CI; Gurmu Y; Velazquez EJ; Morrow DA
    JACC Heart Fail; 2020 Oct; 8(10):834-843. PubMed ID: 32800511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.
    Mc Causland FR; Lefkowitz MP; Claggett B; Packer M; Senni M; Gori M; Jhund PS; McGrath MM; Rouleau JL; Shi V; Swedberg K; Vaduganathan M; Zannad F; Pfeffer MA; Zile M; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 Sep; 24(9):1591-1598. PubMed ID: 34989105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.